L-carnitine is an essential quarternary amine having an important role in the
INTRODUCTION
L-Carnitine is an important cofactor in the fatty acid metabolism and is known to have antioxidant properties (Arduni, 1992; Rani and Panneerselvam, 2001 ). It plays an important role in b-Oxidation of long chain fatty acids in the mitochondria (Brass, 2000) . L-Carnitine is a naturally occurring methylated compound which is responsible for the conversion of long chain fatty acids into acylcarnitine and the transport of acyl groups across the mitochondrial membranes (Kelly, 1998; Szilagyi, 1998) . Carnitine also serves as a buffer for excess acyl-Co A which could accumulate and be deleterious to the cells (Brass, 2000) . Antioxidant effects of L-Carnitine has been reported by several studies where L-carnitine is protective against lipid peroxidation, and it could improve the antioxidant status in rats. In addition, it is associated with scavenging of free radicals in cellular sites (Kalaiselvi and Panneerselvam, 1998; Rani and Panneerselvam, 2002; Sener et al., 2004) . Sialic acid is a name referring to the acetylated derivatives of neuraminic acid. They are part of terminal residues of oligosaccharide chains of mucins, glycoproteins and glycolipids on cell membranes (Sillanaukee et al., 1999; Wang and Brand-Miller, 2003) . Increased sialic acid concentration of serum was reported to be an indicator of early signs of some disorders. For example, plasma sialic acid concentration was increased in cardiovascular disorders, cancer, nephropathies, pneumonia and various other diseases (Lindberg et al., 1991; Shamberger, 1984; Sillanaukee et al., 1999) . Therefore, measuring sialic acid has a diagnostic value in several disease states.
As far as we are aware, there are currently no reports associated with the dose-response study on L-carnitine. Therefore, we attempted to evaluate the effect of 3 different doses of L-Carnitine (100, 250 and 500 mg/kg for 5 days) on blood glutathione (GSH), malondialdehyde (MDA), total sialic acid (TSA) as well as lipid bound (LBSA) and protein bound sialic acid (PBSA) levels in BALB/c mice.
MATERIALS AND METHODS
Forty BALB/c mice (obtained from the University of Kafkas, Animal Research Farm) weighing 25-35 g were randomly divided into 4 groups containing 10 mice each. Group 1 (control) received intraperitoneal (i.p.) injections of isotonic saline solution daily for 5 days. Group 2 was treated with daily i.p. injection of 100 mg/kg L-Carnitine (CARNITENE ® , Sigma-Tau Industrie Farmaceutiche, Pomezia-Italy) for 5 days. Group 3 was treated with 250 mg/kg of L-carnitine for 5 days. Group 4 was injected with 500 mg/kg of L-carnitine (i.p.) for 5 days. Blood samples from the treatment groups were collected from the heart via cardiac puncture under light ether anesthesia on the 6 th day. For GSH analysis, blood was taken into the tube without EDTA and for MDA and sialic acids measurements, blood samples were taken into the EDTA tubes, and were allowed to stand for 1 hour at room temperature. Then, all tubes were centrifuged at 3000 rpm for 10 minutes to separate the plasma. The samples were kept at -25 o C until analyzed. Analyses were carried out by the methods of Beutler (1963) and Yoshoiko (1979) for GSH and MDA levels, respectively. Plasma total sialic acid (TSA) and lipid bound sialic acid (LSA) levels were measured colorimetrically using a spectrophotometer (UV-1201, Shimadzu, Japan) by the method of Sydow (1985) . The concentration of protein bound sialic acid (PBSA) was calculated by subtracting LBSA from TSA. For statistical analysis, differences between the groups were tested by analysis of variance (ANOVA) followed by Duncan test using SPSS for Windows version 6.0. Data were presented as mean ± SEM, and p values less than 0.05 were considered significant.
RESULTS
Plasma TSA, LBSA and PBSA concentrations in mice treated with Lcarnitine at doses of 100, 250 and 500 mg/kg were lower than in the control samples. However, there was a dose dependent reduction in these parameters in L-carnitine treated mice. As the dose of L-carnitine increased, TSA, LSA and PBSA concentrations decreased (Table 1 ). In addition, while serum GSH concentration in the control was significantly lower compared to mice receiving 100, 250 and 500 mg/kg of L-carnitine, MDA concentration appeared to decrease in a dose dependent manner (Table 1) . Moreover, serum GSH concentration in group 2 (Lcarnitine: 100 mg/kg), 3 (L-carnitine: 250 mg/kg) and 4 (L-carnitine: 500 mg/kg) was significantly higher than in the control group. The highest GSH concentration observed was in group 4 (receiving 500 mg/kg of L-carnitine). 
DISCUSSION
While administration of L-carnitine at doses of 100, 250 and 500 mg/kg to mice showed a dose-dependent increase in GSH and decrease in MDA, Lcarnitine applied at 500 mg/kg provided a strong antioxidant action as evidenced by increased GSH and decreased MDA concentrations. Previous studies on the effects of L-carnitine on various types of chemically-induced toxicities indicate that L-carnitine a dose of 500 mg/kg ameliorated the adverse effects in rats (Sener et from chronic renal failure associated with oxidative stress (Sener et al., 2004) . Similarly, in Cisplatin-induced nephrotoxicity where the oxidative stress and lipid peroxidation are tought to play a major role in the pathophysiology of nephrotoxicity, administration of L-carnitine at 500 mg/kg for 10 days in SpragueDawley rats normalized kidney function as evidenced by histopathology, BUN and serum creatinine levels. In addition, L-carnitine at this dose attenuated the increased MDA and reduced GSH levels (Sayed -Ahmed et al, 2004) . Other than nephrotoxicity, L-carnitine at 500 mg/kg was shown to prevent ethanol induced lesions in gastric mucosa and protected against lipid peroxidation as well as normalized GSH of the gastric mucosa in rats (Dokmeci et al. 2005) . In an in vitro study, apoptosis induced by doxorubicin in cardiac myocytes is prevented by Lcarnitine (Andrieu-Abadie et al., 1999). Methamphetamine neurotoxicity, mediated by peroxynitrite radicals, was protected by L-carnitine (Ashraf et al., 2002) . In addition, brain injury associated with hypoxia and ischemia in neonates was ameliorated by L-carnitine. Production of reactive oxygen species is a common finding during ischemia-reperfusion cases (Pallor et al., 1984) . Therefore, L-carnitine may be involved in scavenging of reactive species. Lcarnitine could prevent oxidative damage by increasing oxygen utilization and protecting from ATP depletion. Another way of protection by L-carnitine could be associated with increasing the antioxidant level in tissues, since L-carnitine increases GSH levels (Di Giacomo et al., 1993) . This effect has been also observed by an increase in GSH in our study at doses of 100, 250 and 500 mg/kg with the highest increase in serum GSH of mice injected with 500 mg/kg Lcarnitine. Oxidative stress is one of the leading factors in the initiation of many disease processes (Galle, 2001) . A balanced redox state of the cell is maintained by adequate antioxidant potential against reactive species, otherwise an overwhelmed antioxidant status results in oxidative stress leading to lipid peroxidation, protein and DNA injury (Tylicki et al., 2003) . Glutathione is an important part of antioxidant defense system which plays an important role in preventing the harmful effects of free radicals by scavenging hydroxyradicals and singlet oxygen (Diplock, 1994) . Therefore, reduced GSH may contribute to the decreased level of antioxidant potential leading to oxidative stress which could consequently result in cytotoxicity. An important consequence of enhanced free radical formation due to oxidative stress is lipid peroxidation leading to the breakdown of cellular membranes.
Polyunsaturated fatty acids in membrane phospholipids are the major targets for free radicals which are capable of inducing a chain reaction of lipid peroxidation. These reactions in lipid membranes give rise to the formation of end products which are used to detect free radical damage. One of the important end products measured as an indicator of lipid peroxidation is known to be MDA (De Zwart et al., 1999) . In addition to MDA the release of sialic acid located on the terminal residues of glycolipids of cell membranes could ensue as a result of the breakdown of cell membranes and/or lipid peroxidation. The released sialic acid reaches the plasma, and this could be reflected by the elevated plasma sialic acid concentracion. Elevation of TSA and LBSA concentrations is considered to be the reflection of altered structural integrity of glycolipids in the cellular membranes (O'Kennedy et al., 1991; Shutter et al., 1992) . Indeed, serum sialic acid level in various types of diseases was found to be increased in cancer patients and several types of inflammatory diseases such as arthritis, Crohn's disease and psoriasis (Shamberger, 1984; Silver et al., 1983 ). The increase in the level of sialic acid was also correlated with the rate of cardiovascular mortality (Lindberg et al., 1991) . In addition, serum sialic acid concentrations are increased in chronic glomerulonephritis, chronic renal failure, chronic liver disease and pneumonia (Sillanaukee et al., 1999) . Protection of cellular membranes through L-carnitine could be due also to the action of L-carnitine via detoxification of acetyl groups and free CoA (Fritz and Arrigoni-Martelli, 1993) .
Although L-carnitine applied at 3 different doses (100, 250 and 500 mg/kg) showed an improvement in the antioxidant and protective effect against lipid peroxidation, it appears that L-carnitine applied at 500 mg/kg for 5 days to mice had greater effects on these parameters than the other applied doses (100 and 250 mg/kg).
In conclusion, L-carnitine at 100, 250 and 500 g/kg doses is capable of improving selected blood parameters including MDA, GSH and sialic acid via increasing the antioxidant status and reducing lipid peroxidation, as well as by protecting cellular membranes, with the highest effect seen at 500 mg/kg administered for 5 days.
